"We dream in drug development of something like a 35 percent mortality reduction. This is a major advance."
@SecAzar explains the findings from clinical studies on plasma as a treatment for COVID-19:pic.twitter.com/1FS7nh7Ifs
Director of the National Institutes of Health, have raised concerns about the data on the country’s largest blood plasma study. Their concerns that the data was too weak prompted the Food and Drug Administration to put a hold on granting emergency use for the blood treatment.